Related Experiment Videos
[Desmoid tumor sensitive to tamoxifen]
1Maison Médicale de Lunesse, Isle d'Espagnac.
Presse Medicale (Paris, France : 1983)
|January 22, 1998
Summary
Tamoxifen effectively treated a desmoid tumor in a familial adenomatous polyposis patient after surgery. This treatment offered rapid, sustained tumor regression and symptom relief.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Desmoid tumors are a significant cause of mortality in familial adenomatous polyposis (FAP) patients post-proctocolectomy.
- Treatment for these locally aggressive, non-metastasizing tumors presents considerable challenges.
Observation:
- A young woman with FAP developed a mesenteric desmoid tumor post-coloproctectomy.
- The tumor progressed despite sulindac treatment, leading to subocclusion.
- Tamoxifen (20 mg/day) was administered, resulting in rapid tumor regression and symptom alleviation.
Findings:
- Tamoxifen treatment led to a significant reduction in desmoid tumor size (20-fold).
- The patient experienced sustained symptom relief and remained tumor-free for 4.5 years.
- Tamoxifen was well-tolerated throughout the treatment period.
Implications:
- Tamoxifen represents a viable therapeutic option for managing desmoid tumors in FAP patients.
- This case highlights the potential of tamoxifen in critical clinical scenarios involving unresectable desmoid tumors.
- Further research into tamoxifen's efficacy and long-term outcomes in desmoid tumor management is warranted.